Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44)
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of innovative technologies that may advance progress toward more effective cell replacement therapies for type 1 diabetes (T1D).
General information about this opportunity
Last Known Status
Active
Program Number
RFA-DK-16-004 Federal Agency/Office
Agency: Department of Health and Human ServicesOffice: National Institutes of Health
Type(s) of Assistance Offered
Grant Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. What is the process for applying and being award this assistance?
Deadlines
06/28/2016 Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements. Who do I contact about this opportunity?
Headquarters Office
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
Website Address
http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-004.html
E-mail Address
FBOWebmaster@OD.NIH.GOV
Financial Information
Obligations
$3,000,000.00
